AR119093A1 - INHIBIDORES DE DOPAMINA-b-HIDROXILASA - Google Patents
INHIBIDORES DE DOPAMINA-b-HIDROXILASAInfo
- Publication number
- AR119093A1 AR119093A1 ARP200101584A ARP200101584A AR119093A1 AR 119093 A1 AR119093 A1 AR 119093A1 AR P200101584 A ARP200101584 A AR P200101584A AR P200101584 A ARP200101584 A AR P200101584A AR 119093 A1 AR119093 A1 AR 119093A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- compounds
- solvates
- halo
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a: (a) compuestos de la fórmula (1) (con R¹ a R⁵ y A de acuerdo con lo definido en la presente memoria) y sales o solvatos aceptables para uso farmacéutico de los mismos que son útiles como inhibidores de dopamina-b-hidroxilasa; (b) composiciones farmacéuticas que comprenden tales compuestos, sales o solvatos; (c) el uso de tales compuestos, sales o solvatos en una terapia; (d) métodos terapéuticos de tratamiento por el uso de tales compuestos, sales o solvatos; y (e) procesos e intermedios útiles para la síntesis de tales compuestos. Reivindicación 1: Un compuesto de la fórmula (1), o una sal o solvato aceptable para uso farmacéutico del mismo, caracterizado porque: R¹ es hidrógeno; R² es hidrógeno; y R³ es hidrógeno, metilo, heterociclilo de 6 miembros o CH₂X en el que X es heterociclilo de 5 ó 6 miembros; o R² es metilo; y R³ es metilo, heterociclilo de 5 ó 6 miembros o CH₂X en el que X es heterociclilo de 5 ó 6 miembros; o R² y R³ se combinan, junto con el átomo de N al que están unidos, para formar un N-heterociclilo de 5 ó 6 miembros sustituido de manera opcional con un sustituyente flúor; R⁴ es hidrógeno; y R⁵ es hidrógeno; o R⁴ y R⁵ se combinan, junto con los átomos de carbono a los que están unidos, para formar un anillo de ciclopropilo; y A es un compuesto de fórmula (2), en la que: X¹ es hidrógeno o halo; X¹ es hidrógeno o halo; X² es hidrógeno o halo; X² es hidrógeno o halo; y X³ es hidrógeno; con la condición de que los compuestos clorhidrato de (R)-1-(3-(pirrolidin-1-il)propil)-6-(2,3,5,6-tetrafluorofenil)-2,5,6,7-tetrahidro-3Hpirrol[1,2-c]imidazol-3-tiona, (R)-1-(3-(pirrolidin-1-il)propil)-6-(2,3,5,6-tetrafluorofenil)-2,5,6,7-tetrahidro-3H-pirrol[1,2-c]imidazol-3-tiona y hidrofluoruro de (R)-1-(3-(pirrolidin-1-il)propil)-6-(2,3,6-trifluorofenil)-2,5,6,7-tetrahidro-3H-pirrol[1,2-c]imidazol-3-tiona estén excluidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1908044.9A GB201908044D0 (en) | 2019-06-05 | 2019-06-05 | Dopamine-B-Hydroxylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR119093A1 true AR119093A1 (es) | 2021-11-24 |
Family
ID=67385676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200101584A AR119093A1 (es) | 2019-06-05 | 2020-06-04 | INHIBIDORES DE DOPAMINA-b-HIDROXILASA |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220267331A1 (es) |
EP (1) | EP3980421A1 (es) |
JP (1) | JP2022535423A (es) |
KR (1) | KR20220044246A (es) |
CN (1) | CN113966333A (es) |
AR (1) | AR119093A1 (es) |
AU (1) | AU2020287821A1 (es) |
BR (1) | BR112021023834A8 (es) |
CA (1) | CA3142348A1 (es) |
GB (1) | GB201908044D0 (es) |
IL (1) | IL288323A (es) |
MX (1) | MX2021014941A (es) |
TW (1) | TW202112780A (es) |
WO (1) | WO2020246903A1 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT757677E (pt) | 1994-04-26 | 2003-11-28 | Syntex Llc | Derivados de benzociclohexilimidazoletiona |
US7125904B2 (en) | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
US11434242B2 (en) | 2017-12-04 | 2022-09-06 | Bial—Portela & Ca, S.A. | Dopamine-b-hydroxylase inhibitors |
-
2019
- 2019-06-05 GB GBGB1908044.9A patent/GB201908044D0/en not_active Ceased
-
2020
- 2020-06-01 TW TW109118270A patent/TW202112780A/zh unknown
- 2020-06-03 CA CA3142348A patent/CA3142348A1/en active Pending
- 2020-06-03 KR KR1020217042170A patent/KR20220044246A/ko unknown
- 2020-06-03 EP EP20735464.8A patent/EP3980421A1/en not_active Withdrawn
- 2020-06-03 WO PCT/PT2020/050022 patent/WO2020246903A1/en unknown
- 2020-06-03 US US17/615,987 patent/US20220267331A1/en active Pending
- 2020-06-03 MX MX2021014941A patent/MX2021014941A/es unknown
- 2020-06-03 CN CN202080041189.2A patent/CN113966333A/zh active Pending
- 2020-06-03 AU AU2020287821A patent/AU2020287821A1/en not_active Abandoned
- 2020-06-03 JP JP2021571969A patent/JP2022535423A/ja active Pending
- 2020-06-03 BR BR112021023834A patent/BR112021023834A8/pt not_active Application Discontinuation
- 2020-06-04 AR ARP200101584A patent/AR119093A1/es unknown
-
2021
- 2021-11-23 IL IL288323A patent/IL288323A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113966333A (zh) | 2022-01-21 |
US20220267331A1 (en) | 2022-08-25 |
MX2021014941A (es) | 2022-01-24 |
BR112021023834A2 (pt) | 2022-01-04 |
AU2020287821A1 (en) | 2022-01-06 |
GB201908044D0 (en) | 2019-07-17 |
KR20220044246A (ko) | 2022-04-07 |
WO2020246903A1 (en) | 2020-12-10 |
CA3142348A1 (en) | 2020-12-10 |
EP3980421A1 (en) | 2022-04-13 |
JP2022535423A (ja) | 2022-08-08 |
TW202112780A (zh) | 2021-04-01 |
BR112021023834A8 (pt) | 2023-02-28 |
IL288323A (en) | 2022-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
CR20200532A (es) | Compuestos de heteroarilo tetracíclicos | |
AP1122A (en) | Therapeutically active compounds based on based on based on indazole bioisostere replacement of catechol in PDE4 inhibitors. | |
MX2022014312A (es) | Inhibidores de sarcomero cardiaco. | |
RU2015108898A (ru) | 3-ЦИКЛОГЕКСЕНИЛ И ЦИКЛОГЕКСИЛ ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ И ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ | |
AR111820A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue | |
AR102213A1 (es) | Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades | |
AR110753A1 (es) | Inhibidores selectivos de jak1 | |
AR076850A1 (es) | Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa. | |
AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
JOP20190113A1 (ar) | مثبطات بروتون تيروزين كيناز | |
AR066063A1 (es) | Derivados de triazol que son antagonistas de smo | |
AR083019A1 (es) | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden | |
CO6460737A2 (es) | N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos | |
AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento | |
DE60214401D1 (de) | Hetero-bicyclische crf antagonisten | |
EA019901B1 (ru) | Карбамоильные производные бициклических карбониламинопиразолов в качестве пролекарств | |
MY165634A (en) | Pyrazole compounds having therapeutic effect on multiple myeloma | |
MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
RU2015113597A (ru) | Производные аминоизохинолина в качестве ингибиторов протеинкиназы | |
DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
PE20221454A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 |